Pay in 4 interest-free payments of $6.25 Learn more
Ships within 48 hours · Estimated delivery Sep 3 - Sep 8
The SELECT trial (2023) demonstrated a 20% reduction in major adverse cardiovascular events in non-diabetic obese patients establishing cardiovascular research as a major frontier for GLP-1 agonist compounds
1 EDKA Precipitating Factors SGLT2i: In the United States, SGLT2i (canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin) are currently approved to treat only T2DM, not T1DM
Central nervous system (CNS) receives peripheral relevant information that are able to regulate individual's energy balance through metabolic, neural, and endocrine signals
1 According to investigators, the trial is the first to test the cardiovascular benefits of an oral glucagon-like peptide-1 (GLP-1) agonist
US$ 22.86
US$ 27.01
US$ 24.07
